©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. May 28, 2025; 31(20): 104038
Published online May 28, 2025. doi: 10.3748/wjg.v31.i20.104038
Published online May 28, 2025. doi: 10.3748/wjg.v31.i20.104038
Upadacitinib for ulcerative colitis and pyoderma gangrenosum in a patient with schizophrenia on long-term risperidone: A case report
Sheng-Duo He, Yu Tian, Department of Gastroenterology, Peking University First Hospital, Beijing 100034, China
Author contributions: He SD followed up the patient and wrote the manuscript; Tian Y diagnosed and treated the patient, organized clinical data, participated in discussions on dermatological diagnosis and treatment; all authors have read and approved the final manuscript.
Informed consent statement: The patient provided informed written consent prior to study enrollment.
Conflict-of-interest statement: The authors have no conflicts of interest.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Corresponding author: Yu Tian, MD, Chief Physician, Department of Gastroenterology, Peking University First Hospital, No. 8 Xishiku Street, Xicheng District, Beijing 100034, China.
Received: January 22, 2025
Revised: March 27, 2025
Accepted: May 7, 2025
Published online: May 28, 2025
Processing time: 126 Days and 17.2 Hours
Revised: March 27, 2025
Accepted: May 7, 2025
Published online: May 28, 2025
Processing time: 126 Days and 17.2 Hours
Core Tip
Core Tip: Due to the potential anti-inflammatory effect of risperidone via the tumor necrosis factor pathway, patients with new-onset ulcerative colitis (UC) who have been receiving long-term risperidone cannot achieve a good therapeutic effect with anti-tumor necrosis factor therapy. We report the successful treatment of a patient with UC combined with pyoderma gangrenosum using upadacitinib, with no adverse events during the 6-month follow-up period.